Baxter Launches At-Risk Generic During Appeal
A favorable district court ruling in late September 2005 gave Baxter the green light to begin marketing sevoflurane, the active ingredient in Ultane. But Abbott appealed the decision, prompting some analysts to suspect the launch would be delayed.
Abbott sued Baxter in March 2001, when the generic maker filed an Abbreviated New Drug...
To view the full article, register now.